Overreached Endurance Athletes Demonstrate Alterations in Exercising Carbohydrate Utilization Applicable to Training Monitoring

Alexandra M. Coates,1 Kyle M.A. Thompson,1 Monica M. Grigore,1 Ryleigh E. Baker,1 Christopher Pignanelli,1 Alexa A. Robertson,1 Sara M. Frangos,2 Christian P. Cheung,1 and Jamie F. Burr1

1The Human Performance and Health Research Laboratory, Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada. 2 Mitochondrial Metabolism Laboratory, Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.

ABSTRACT

Purpose: To investigate whether carbohydrate utilization is altered during exercise in overreached endurance athletes, and to examine the utility of continuous glucose monitors (CGM) to detect overreaching status. Methods: Eleven endurance athletes (M:8, F:3) completed a 5-week training block consisting of 1-week of reduced training (PRE), 3-weeks of high-intensity overload training (POST), and 1-week of recovery training (REC). Participants completed a Lamberts and Lambert Submaximal Cycling Test (LSCT) and 5km time-trial at PRE, POST, and REC timepoints, 15min following the ingestion of a 50g glucose beverage with glucose recorded each minute via CGM. Results: Performance in the 5km time-trial was reduced at POST (∆-7±10W, P=0.04, ηp²=0.35) and improved at REC (∆12±9W from PRE, P=0.01, ηp²=0.66), with reductions in peak lactate (∆-3.0±2.0mmol/L, P=0.001, ηp²=0.71), peak HR (∆-6±3bpm, P<0.001, ηp²=0.86), and Hooper-Mackinnon well-being scores (∆10±5a.u., P<0.001, ηp²=0.79), indicating athletes were functionally-overreached. The respiratory exchange ratio was suppressed at POST relative to REC during the 60% (POST: 0.80±0.05, REC: 0.87±0.05, P<0.001, ηp²=0.74), and 80% (POST:0.93±0.05, REC: 1.00±0.05, P=0.003, ηp²=0.68) of HR-matched submaximal stages of the LSCT. CGM glucose was reduced during HR-matched submaximal exercise in the LSCT at POST (P=0.047, ηp²=0.36), but not the 5km time-trial (P = 0.07, ηp² =0.28) in overreached athletes. Conclusion: This preliminary investigation demonstrates a reduction in blood glucose and carbohydrate oxidation during submaximal exercise in overreached athletes. The use of CGM during submaximal exercise following standardised nutrition could be employed as a monitoring tool to detect overreaching in endurance athletes.

INTRODUCTION

The purpose of exercise training is to provide an overload stimulus that, upon recovery, allows for physiological adaptation and eventual performance enhancement. This overload training typically results in an acute state of fatigue that should resolve quickly in the following hours or days (1). However, with insufficient recovery, an athlete may experience functional or non-functional overreaching, which are distinguishable from acute fatigue by a prolonged decrement in performance that takes several days-to-weeks (functional overreaching), or weeks-to-months (non-functional overreaching), to resolve (1). Functional overreaching is a common occurrence in endurance sports, as the underperformance following an overload training block is often considered a necessary component of training to induce performance
enhancement (1–3). However, functional overreaching has been demonstrated to result in an inferior supercompensation following recovery compared to acute fatigue (3), and is accompanied by additional maladaptive physiological symptoms including: lower exercising cardiac output (4, 5), reductions in exercising catecholamines (5, 6), increases in resting muscle sympathetic nerve activity (7), a blunting of physiological training adaptations (3, 7, 8), and an increased incidence of illness (9). It is, therefore, important that athletes and coaches avoid functional and non-functional overreaching in order to prevent unnecessary reductions in training capacity, health, and performance.

While overreaching and the more severe overtraining syndrome (1, 10) have been studied for decades (1), the underlying mechanisms that drive underperformance from overtraining remain incompletely understood. Attempts to understand the direct effects of overtraining have further been confounded by studies that purported to assess overreaching or overtraining syndrome but were influenced by participants entering a state of low energy availability (11, 12) during training. From a metabolic perspective, it has been demonstrated repeatedly that overreaching is accompanied by a reduction in circulating blood lactate at intensities above ~70% of maximal oxygen consumption (VO₂max) (5, 6, 13); however, substrate utilization during exercise in overreached athletes has rarely been assessed. Recently, recreationally active individuals who underwent a 3-week high-intensity interval training intervention that resulted in a performance plateau were shown to have reductions in exercising capillary glucose concentrations during high-intensity cycling that resolved following recovery (14, 15). This was accompanied by a reduction in intrinsic respiration of isolated-mitochondria from skeletal muscle and elevations in fat utilization during submaximal exercise, but with no change in muscle glycogen stores, fasted circulating free-fatty acids, or alterations in resting metabolic rate (15) that would indicate insufficient energy availability as the primary mechanism (16). Notably, this research was not performed in trained athletes, and it is difficult to assess overreaching status in untrained populations due to the greater magnitude of positive physiological training adaptations that occur compared to those who are already well-trained (17). However, if circulating glucose and/or glucose utilization during exercise is indeed altered with overreaching in endurance-trained athletes, this may provide an additional avenue for athletic monitoring, particularly with continuous glucose monitors (CGM) recently repurposed as biometric wearables for non-diabetic athletic use (18).

Numerous models have been suggested for monitoring and diagnosing overreaching status amongst endurance athletes (13, 14, 19, 20). While sustained underperformance is required to diagnose a verifiable state of overreaching (1), performance is difficult to assess
due to normal day-to-day variability and can be confounded by the initial training status of the individual (17, 21). As such, other markers such as reductions in exercising HR and lactate, and elevated RPE at a submaximal exercise load (typically ≥70% of VO$_{2\text{max}}$) (5, 13, 14, 19) can be used to accompany a suspected reduction in performance. Mood states and subjective reports of fatigue are consistently shown to be worsened with overreaching; however, these likely cannot distinguish between acute fatigue and overreaching as stand-alone measures (19, 20).

Lastly, the Lamberts and Lambert Submaximal Cycle Test (LSCT) was designed to detect fatigue and predict performance in cyclists without the requirement of maximal exercise testing (22). Briefly, the LSCT requires athletes to cycle for 6 min at 60% of maximal HR (HRmax), 6 min at 80% HRmax, and 3 min at 90% of HRmax. With overreaching, a greater effort must be exerted to achieve the prescribed HR, thus an elevation in cycling power output and RPE in the 80% and 90% of HRmax stages can indicate overreaching. This test has been shown to be useful in detecting overreaching status in female cyclists (20). Unlike low-energy availability which is detectable with resting measures (23), overreaching typically requires submaximal or maximal exercise prior to detection (13, 17). The addition of a wearable device that could provide further feedback to detect overreaching during regular (submaximal) training would be beneficial for athletes and coaches.

The purpose of this investigation was to examine whether carbohydrate utilization is indeed altered during submaximal or maximal exercise in overreached endurance athletes, with the secondary purpose of testing the utility of CGMs and other training monitoring techniques for detecting overreaching status. We hypothesized that overreached endurance athletes would have a reduced respiratory exchange ratio (RER) during submaximal exercise, indicating reduced carbohydrate utilization, and a CGM detectable decrease in circulating glucose during exercise. It was expected that this response would return to baseline after a week of recovery training.
METHODS

Experimental Design

Fifteen endurance athletes between the ages of 18-50 y who self-reported more than 7 h/week of endurance training were recruited for this study. The sample size was selected based on a previous investigation demonstrating altered glucose regulation following overload training in 11 untrained subjects (15). Inclusion criteria stipulated athletes to have no known illnesses, diseases, or active use of medication, which was verified with the use of the PAR-Q+ screening questionnaire (24). To determine baseline training load, participants recorded their training using an online activity tracking application (Strava Inc, United States of America) ≥ one week prior to participating in the study. Training sessions were tracked thereafter for the duration of the study. Using baseline training records, a single investigator programmed individual training plans with input from participants. Typical training duration was reduced by ~50% in the first week to ensure participants were neither overreached nor acutely fatigued for baseline testing. During weeks 2, 3, and 4, athletes maintained their typical training program with maintenance of duration and intensity in each session. In addition, participants performed two sprint-interval sessions and one exercise-test session (explained below) each week in the Human Performance Laboratory, with the goal of achieving ~150% of typical training duration (17). Sprint-interval sessions for overload training consisted of 4-6 repetitions of 30 s maximal Wingate tests at a load of 7.5% of body weight, separated by 4 min of active recovery. The overload training commenced with 4 Wingate tests, and one additional interval was added each week. The final week of training was a recovery week, in which the duration of the training was reduced by ~50% and matched to week 1. Primary outcome measures were evaluated at the end of weeks 1 (PRE), 4 (POST), and 5 (REC), with resting-measures visits occurring the day after the exercise-test visit.
Continuous glucose monitor sensors (CGM; Supersapiens, Abbott Libre Sense, Illinois, USA) were inserted into the subcutaneous fat pad located over the triceps brachii as per manufacturer instructions. CGM sensors were activated at least 1 day prior to baseline testing at PRE and were replaced and re-initiated at weeks 3 and 5 owing to the 14-day lifespan of sensors. Minute-by-minute glucose was recorded in the native software application for the duration of the study. Participants were instructed to increase their energy intake in weeks 2-4 to avoid the occurrence of low energy availability, but energy intake was not tracked. Menstrual cycle or the phase of oral contraceptive was not controlled in this study due to the nature of the 5-week training-block. This study is the first in a series of studies examining the metabolic, cardiovascular, and neuromuscular consequences of overreaching, and only the relevant methods are described herein. This study was approved by the institutional research ethics board, and all participants provided written informed consent.

Overreaching Status

Overreaching was defined a priori as the presentation of 4 of the 5 following criteria from PRE to POST: 1) a reduction in average power output in the 5 km time-trial, 2) a reduction in HRmax in the 5 km time-trial (13, 19), 3) a reduction in peak lactate upon completion of the 5 km time-trial (13), 4) a worsening of well-being scores using a Hooper-Mackinnon scale (25), and/or 5) a positive overreaching status in the LSCT, defined as an increase in power output at 80% of HRmax and increases in ratings of perceived exertion (RPE) at 80 and 90% of HRmax (20). The experimental design is illustrated in Figure 1.
Figure 1. Experimental design of the 5-week overload training study in recreational endurance athletes. Weeks 1 (PRE) and 5 (REC) were prescribed at ~50% of regular training duration, with weeks 2, 3, and 4 (OL) at ~150% of regular training duration. PRE, pre-overload training. OL, overload. REC, recovery. RMR, resting metabolic rate. HRV, heart rate variability.

Maximal Incremental Exercise Test

During the initial visit, participants completed an incremental cycling test to exhaustion on an electromagnetically braked cycle ergometer (Velotron, Quarq, South Dakota, USA). Expired gases were analyzed throughout the test using breath-by-breath open-circuit indirect calorimetry (Cosmed Quark CPET, Rome, Italy) to determine peak oxygen consumption (VO₂ peak) and HRmax. HR data was collected via chest strap and transmitted to the metabolic cart via ANT+ telemetry (Garmin, Olathe, Kansas, USA). The incremental cycling protocol began at 100 W for female or 160 W for male participants, and power was increased by 20 W for females or 30 W for males every minute until the participant could not sustain a cadence over 70 rpm or stopped due to volitional exhaustion. VO₂ peak was determined as the highest 30 s rolling average in the test.

Exercise-Test Visits

Weekly exercise-test visits were performed in the morning and participants attended the laboratory after fasting for ≥7 h and avoiding caffeine, stimulants, recreational drugs, and alcohol for 24h. Upon arrival, participants completed a Hooper-Mackinnon well-being scale (25), which inquired about subjective ratings of fatigue, stress, sleep, muscle soreness, training enjoyment, irritability, and overall health. The scale is ranked from 1-7 with 1 being "very-very
low” or “good”, and 7 being “very-very high” or “bad”. Participants then drank 50 g of glucose (Trutol, Thermo Fisher, USA), and waited 15 min before cycling. During this time, participants were instrumented with a Polar chest strap (Polar, Kempele, Finland) to assess exercising HR, which transmitted via Bluetooth to Racermate software (Racermate, Seattle, Washington, USA). At 15 min post-glucose ingestion, participants began the LSCT, which consisted of 6 min of cycling at 60% of their HRmax achieved in the maximal incremental exercise test, 6 min at 80% of HRmax, and 3 min at 90% of HRmax as previously described (22, 26). Cycling power and HR were recorded continuously, with the first minute of each stage of the LSCT excluded from analysis as per LSCT protocol (22, 26). Ratings of perceived exertion (RPE) on a scale of 6-20 were recorded in the final minute of each stage. Participants were given 10 min of rest following the LSCT prior to a 5 km cycling time-trial on the same Velotron cycle ergometer and Racermate software. Peak HR was recorded at the end of the 5 km time-trial.

At PRE, POST, and REC time points, additional metabolic, and hematologic data collection occurred. Before glucose ingestion, ~10 mL of blood was taken from a venous sample for analysis of fasted pre-exercise epinephrine, leptin, and hematocrit. Following 50 g glucose ingestion to maintain circulating glucose availability across days, participants were fitted with a Hans-Rudolph facemask for breath-by-breath indirect calorimetry to assess mean ventilation (VE), volume of oxygen consumed (VO₂), volume of carbon dioxide expired CO₂ (VCO₂), and respiratory exchange ratio (RER) during both the LSCT and the 5 km time-trial. The first minute of each stage of the LSCT was excluded from data analysis for the indirect calorimetry. Substrate utilization derived from RER was focused on the 60 and 80% of HRmax stages, as RER cannot be used to assess substrate utilization during non-steady state exercise or when values are >1.0 (27).

Fingersticks were performed in the final minute of each stage of the LSCT and immediately following completion of the 5 km time-trial for analysis of blood lactate (Lactate Plus, Nova Biomedical, Waltham, MA, USA). Minute-by-minute glucose concentrations were recorded via the integrated CGM device software, and end-stage glucose and lactate were recorded simultaneously for direct comparison. For the assessment of minute-by-minute glucose and glucose area-under-the-curve (AUC) during the 5 km time-trial, only the first 7 min (range 7-9 min) were included for analysis, as the minute-by-minute data points did not allow for precise sampling to occur throughout the test. During the 10 min break between the LSCT and the 5 km time-trial, participants were instrumented with an in-dwelling brachial catheter (BD Insyte, Franklin Lakes, New Jersey, USA) to allow for rapid venous sampling in the final 30 s
the time-trial for assessment of maximal exercising plasma epinephrine. The exercise-test visit timeline is depicted in Figure 2.

Figure 2. Timeline of the exercise-test visits performed during the 5-week overload training study in recreational endurance athletes. Full experimental procedures occurred at weeks 1 (PRE), 4 (OL), and 5 (REC), with paired-down visits (Hooper-Mackinnon well-being scale, cycling HR, and CGM glucose) occurring in weeks 2 and 3 of the overload training block. Timeline not to scale. Checklist: Hooper-Mackinnon well-being scale. Vacutainer 1: venous sample for epinephrine, hematocrit, and leptin. Drink: 50 g of glucose. RPE: rating of perceived exertion. Blood drop: assessment of lactate and recording of glucose. Vacutainer 2: venous sample for exercising epinephrine. Created with BioRender.

Resting Visits

Resting visits were performed the day after the exercise-test visits at PRE, POST, and REC, and following an overnight fast (≥7 h) with the avoidance of caffeine, stimulants, recreational drugs, and alcohol for 24 h. Resting metabolic rate (RMR), body mass, and leptin were chosen to assess whether a participant was in a state of low energy availability. Body mass was assessed with the same digital scale as above. RMR was measured via indirect calorimetry using a Cosmed Hans Rudolph face mask for breath-by-breath analysis of expired gases and assessed while the participant lay supine in a dark and quiet room, with blankets to maintain body temperature. Data was collected for 20 min, and a 5 min period with a VO$_2$ coefficient of variation <10% was extracted in the last 10 min according to best-practise guidelines (28). The mean RMR, VO$_2$, and RER were recorded from the 30 s rolling averages of the 5 min segment.

Autonomic state was assessed via measures of heart rate variability (HRV) collected using a Polar chest strap. Normal R-R intervals were transmitted to the Elite HRV (Asheville, NC, USA) application during the final 5 min of the 20 min RMR resting period. Measures of resting
HR, and ln RMSSD were selected to provide an accurate assessment of vagal activity in a short-time period (29). The Elite HRV application has been demonstrated to provide valid and reliable HRV outputs in endurance athletes (30).

Blood Testing and Analysis

Resting and fasted venous blood was collected into a 6 mL serum, silicone-coated, vacutainer (BD Vacutainer, Franklin Lakes, New Jersey, USA) for the assessment of serum leptin, and a 4 mL K2 EDTA vacutainer (BD Vacutainer, Franklin Lakes, New Jersey, USA) for the assessment of plasma epinephrine. The K2 EDTA tube was immediately placed on ice, and centrifuged (Heraeus, Labofuge 400R, Langenselbold, Germany) at 2000 rcf and 4°C for 10 min as quickly as possible, before separating the plasma and storing at -80°C for future analysis. Following 30 min to allow for serum separation, the serum vacutainer was similarly centrifuged as above, and sent for analysis at an accredited laboratory (LifeLabs Medical Laboratory, Guelph, Ontario, Canada). Hematocrit was measured using whole blood and a microcapillary reader (Damon/IEC Division, MA, USA). At the end of the 5 km time-trial, the indwelling catheter was flushed, and a venous sample was taken in a 4 mL K2 EDTA vacutainer for assessment of peak exercising plasma epinephrine and processed as above. Plasma epinephrine was analyzed in triplicate using a commercially available high-sensitivity enzyme linked immunosorbent assay (Adrenaline High-Sensitive ELISA, Diagnostika GMBH, LOT#AS114).

Statistical Analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences software (SPSS version 29, IBM, Armonk, New York) and Prism 10 (GraphPad Software, LLC, La Jolla, California). Data were assessed for normality using the Shapiro-Wilk test, and non-normally distributed data were analyzed using nonparametric tests (Friedman’s two-way analysis of variance by ranks). Exercise test data was collected over all 5 weeks; however, overreaching status was determined between PRE (week 1) and POST (week 4) measures only via paired Student’s t-tests. Further interrogation into training status including training duration, LSCT and 5 km time-trial outcomes, and Hooper-Mackinnon well-being scores were examined across the 5 weeks using 1x5 repeated-measures ANOVA. Outcome measures including blood, metabolic data, and resting measures collected at PRE (week 1), POST (week 4), and REC (week 5) time points were assessed via repeated measures ANOVA. Greenhouse-
Geisser corrections were applied if groups lacked sphericity, and Bonferroni adjustments were made for post hoc analysis when significant interactions were identified. Pearson’s correlations were performed to assess the relationships between change score variables calculated as (POST-PRE). Data are presented as Mean ± SD unless they were not normally distributed - in which case median and interquartile range (25th and 75th percentile) are presented. Effect sizes are presented as partial eta squared ($\eta^2_p$) for repeated-measures ANOVA, and Kendall W for Friedman’s two-way analysis of variance by ranks. An a priori alpha level for significance was selected at $P \leq 0.05$.

**Results**

**Participant Characteristics & Training Adherence**

Fifteen athletes were recruited for the study; however, one participant dropped out after the first week due to an unrelated injury, and three participants failed to meet the criteria to designate them as unequivocally overreached. As such, results are presented for 11 overreached athletes (n=3 females). All of the athletes fit the description of tier 2 “trained/developmental” athletes, with 1 participant fitting the tier 3 “highly trained/ national level” criteria (31). Participants were 28±6 y, weighed 74.7±11.3 kg, with a height of 176±8 cm, and a BMI of 24.1±2.5 kg/m². Average VO₂ peak was 56.5±7.3 ml·kg⁻¹·min⁻¹ with a maximal aerobic cycling power of 373±76W. All female athletes were on hormonal contraceptives. Participants were instructed to decrease their training loads to ~50% of their regular training duration for weeks 1 and 5, however, week 1 was 78±24% and week 5 was 61±18% of their baseline training duration. Overload training weeks 2-4 were on average 144±32% of baseline training volume (see Table 1).
Table 1. Training characteristics, exercise-test measures, and markers of overreaching for the 5-week overload training study in recreational endurance athletes.

<table>
<thead>
<tr>
<th>Training Load Marker</th>
<th>Week 1 (PRE)</th>
<th>Week 2 (OL)</th>
<th>Week 3 (OL)</th>
<th>Week 4 (POST)</th>
<th>Week 5 (REC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Training Duration (h)</td>
<td>6.4±2.2 kg/yr</td>
<td>11.3±3.0 kg/yr</td>
<td>13.1±3.9 kg/yr</td>
<td>11.3±4.7 kg/yr</td>
<td>5.1±1.7 kg/yr</td>
</tr>
<tr>
<td>Training Duration (% baseline)</td>
<td>78±24 kg/yr</td>
<td>131±27 kg/yr</td>
<td>161±28 kg/yr</td>
<td>139±49 kg/yr</td>
<td>61±18 kg/yr</td>
</tr>
<tr>
<td><strong>LSCT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average Power 60% (W)</td>
<td>114±32 kg/yr</td>
<td>112±28 kg/yr</td>
<td>117±34 kg/yr</td>
<td>115±34 kg/yr</td>
<td>116±35 kg/yr</td>
</tr>
<tr>
<td>Average Power 80% (W)</td>
<td>219±52 kg/yr</td>
<td>226±53 kg/yr</td>
<td>227±57 kg/yr</td>
<td>223±59 kg/yr</td>
<td>225±59 kg/yr</td>
</tr>
<tr>
<td>Average Power 90% (W)</td>
<td>271±63 kg/yr</td>
<td>277±69 kg/yr</td>
<td>280±68 kg/yr</td>
<td>287±74 kg/yr</td>
<td>274±70 kg/yr</td>
</tr>
<tr>
<td>RPE end of 60% (6-20)</td>
<td>8 (8-9) kg/yr</td>
<td>8 (7-8) kg/yr</td>
<td>8 (7-9) kg/yr</td>
<td>8 (7-9) kg/yr</td>
<td>8 (7-8) kg/yr</td>
</tr>
<tr>
<td>RPE end of 80% (6-20)</td>
<td>13 (12-13) kg/yr</td>
<td>13 (13-14) kg/yr</td>
<td>13 (13-15) kg/yr</td>
<td>13 (13-15) kg/yr</td>
<td>13 (12-14) kg/yr</td>
</tr>
<tr>
<td>RPE end of 90% (6-20)</td>
<td>16 (16-17) kg/yr</td>
<td>17 (16-17) kg/yr</td>
<td>17 (16-18) kg/yr</td>
<td>17 (16-18) kg/yr</td>
<td>16 (16-17) kg/yr</td>
</tr>
<tr>
<td>Lactate end of 60% (mmol/L)</td>
<td>1.7±0.7 kg/yr</td>
<td>- kg/yr</td>
<td>- kg/yr</td>
<td>1.6±1.0 kg/yr</td>
<td>1.5±0.4 kg/yr</td>
</tr>
<tr>
<td>Lactate end of 80% (mmol/L)</td>
<td>3.7±1.8 kg/yr</td>
<td>- kg/yr</td>
<td>- kg/yr</td>
<td>3.6±2.0 kg/yr</td>
<td>3.8±1.7 kg/yr</td>
</tr>
<tr>
<td>Lactate end of 90% (mmol/L)</td>
<td>7.1±2.1 kg/yr</td>
<td>- kg/yr</td>
<td>- kg/yr</td>
<td>7.7±2.1 kg/yr</td>
<td>8.5±2.8 kg/yr</td>
</tr>
<tr>
<td>Glucose prior to LSCT (mmol/L)</td>
<td>6.3±0.8 kg/yr</td>
<td>6.4±1.7 kg/yr</td>
<td>6.0±0.9 kg/yr</td>
<td>5.6±0.7 kg/yr</td>
<td>6.1±0.7 kg/yr</td>
</tr>
<tr>
<td>Glucose end of 60% (mmol/L)</td>
<td>7.8±1.1 kg/yr</td>
<td>7.4±1.5 kg/yr</td>
<td>7.1±1.0 kg/yr</td>
<td>7.1±0.9 kg/yr</td>
<td>7.3±0.9 kg/yr</td>
</tr>
<tr>
<td>Glucose end of 80% (mmol/L)</td>
<td>8.0±1.6 kg/yr</td>
<td>7.6±1.8 kg/yr</td>
<td>7.4±1.3 kg/yr</td>
<td>7.4±1.0 kg/yr</td>
<td>7.8±1.1 kg/yr</td>
</tr>
<tr>
<td>Glucose end of 90% (mmol/L)</td>
<td>7.8±1.7 kg/yr</td>
<td>7.3±1.9 kg/yr</td>
<td>7.0±1.4 kg/yr</td>
<td>7.2±1.5 kg/yr</td>
<td>7.7±1.4 kg/yr</td>
</tr>
<tr>
<td><strong>5 km time-trial</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average Power (W)</td>
<td>296±79 kg/yr</td>
<td>286±75 kg/yr</td>
<td>280±77 kg/yr</td>
<td>289±76 kg/yr</td>
<td>308±79 kg/yr</td>
</tr>
<tr>
<td>Time (m:ss)</td>
<td>7:58±0:48 kg/yr</td>
<td>8:03±0:46 kg/yr</td>
<td>8:03±0:45 kg/yr</td>
<td>8:02±0:44 kg/yr</td>
<td>7:50±0:44 kg/yr</td>
</tr>
<tr>
<td>Lactate end of TT (mmol/L)</td>
<td>14.3±2.2 kg/yr</td>
<td>- kg/yr</td>
<td>- kg/yr</td>
<td>11.3±2.3 kg/yr</td>
<td>14.5±2.1 kg/yr</td>
</tr>
<tr>
<td>Glucose end of TT (mmol/L)</td>
<td>6.3±1.3 kg/yr</td>
<td>5.5±1.1 kg/yr</td>
<td>5.6±1.6 kg/yr</td>
<td>6.0±1.9 kg/yr</td>
<td>6.9±2.1 kg/yr</td>
</tr>
<tr>
<td>Peak HR (bpm)</td>
<td>186±6 kg/yr</td>
<td>182±7 kg/yr</td>
<td>180±8 kg/yr</td>
<td>180±7 kg/yr</td>
<td>184±7 kg/yr</td>
</tr>
<tr>
<td>RPE end (6-20 a.u.)</td>
<td>19±1 kg/yr</td>
<td>19±1 kg/yr</td>
<td>19±1 kg/yr</td>
<td>19±1 kg/yr</td>
<td>19±1 kg/yr</td>
</tr>
<tr>
<td><strong>Total well-being scale (7-49 a.u.)</strong></td>
<td>21±5 kg/yr</td>
<td>25±5 kg/yr</td>
<td>27±5 kg/yr</td>
<td>31±5 kg/yr</td>
<td>21±5 kg/yr</td>
</tr>
<tr>
<td>Fatigue (1-7 a.u.)</td>
<td>3 (2-4) kg/yr</td>
<td>4 (3-5) kg/yr</td>
<td>5 (4-5) kg/yr</td>
<td>5 (5-6) kg/yr</td>
<td>3 (3-4) kg/yr</td>
</tr>
<tr>
<td>Stress (1-7 a.u.)</td>
<td>4 (2-4) kg/yr</td>
<td>4 (3-4) kg/yr</td>
<td>5 (4-3) kg/yr</td>
<td>4 (3-5) kg/yr</td>
<td>3 (3-4) kg/yr</td>
</tr>
<tr>
<td>Sleep (1-7 a.u.)</td>
<td>3 (3-4) kg/yr</td>
<td>4 (3-5) kg/yr</td>
<td>3 (3-5) kg/yr</td>
<td>4 (3-5) kg/yr</td>
<td>4 (3-4) kg/yr</td>
</tr>
<tr>
<td>Muscle soreness (1-7 a.u.)</td>
<td>2 (1-3) kg/yr</td>
<td>4 (3-5) kg/yr</td>
<td>4 (4-5) kg/yr</td>
<td>5 (5-6) kg/yr</td>
<td>2 (1-3) kg/yr</td>
</tr>
<tr>
<td>Training enjoyment (1-7 a.u.)</td>
<td>3 (2-4) kg/yr</td>
<td>3 (3-4) kg/yr</td>
<td>3 (3-4) kg/yr</td>
<td>5 (3-5) kg/yr</td>
<td>3 (3-4) kg/yr</td>
</tr>
<tr>
<td>Irritability (1-7 a.u.)</td>
<td>3 (2-4) kg/yr</td>
<td>3 (3-4) kg/yr</td>
<td>4 (3-4) kg/yr</td>
<td>4 (4-5) kg/yr</td>
<td>3 (2-3) kg/yr</td>
</tr>
<tr>
<td>Overall health (1-7 a.u.)</td>
<td>3 (2-3) kg/yr</td>
<td>3 (2-4) kg/yr</td>
<td>3 (2-4) kg/yr</td>
<td>4 (4-4) kg/yr</td>
<td>3 (2-4) kg/yr</td>
</tr>
</tbody>
</table>

PRE, pre-overload training; OL, overload training; POST, post-overload training; REC, post-recovery training. LSCT, Lamberts submaximal cycling test. Stage intensities were 60%, 80%, and 90% of maximal heart rate. TT, time-trial. Total well-being scale: Hooper-Mackinnon well-being scale. Data as Mean ± SD or median (1-3 quartile). Significance adjusted with Bonferroni corrections. *P≤0.05 different from week 1. †P≤0.05 different from week 2. ‡P≤0.05 different from week 3. §P≤0.05 different from week 4. ¶P≤0.05 different from week 5.
Overreaching Status

When comparing week 1 (PRE) with week 4 (POST) to assess overreaching status, average power output in the 5 km time-trial was suppressed by 7±10W (P=0.04, $\eta_p^2=0.35$). Peak lactate ($\Delta-3.0\pm2.0$ mmol/L, P=0.001, $\eta_p^2=0.71$) and peak HR ($\Delta-6\pm3$ bpm, P<0.001, $\eta_p^2=0.86$) at the end of the 5 km time-trial were reduced at POST. There was no difference between power output at 80% of HRmax in the LSCT ($\Delta-3\pm-14$W, P=0.5, $\eta_p^2=-0.06$), or RPE at 80% of HRmax ($\Delta1 (0\pm2)$, P=0.16, W=0.18), but RPE at 90% was significantly elevated ($\Delta1 (0\pm2)$, P=0.03, W=0.45). The Hooper-Mackinnon scale demonstrated elevated deleterious well-being scores following the 3-week overload training ($\Delta10\pm5$ a.u., P<0.001, $\eta_p^2=0.79$) (see Table 1).

Training Load Monitoring

Across all 4-weeks of training and into recovery, the LSCT was insufficient to detect mean training stress, as power at 80% HRmax did not significantly increase from PRE to POST, RPE was unchanged at 80% HRmax and only RPE at 90% HRmax was elevated at POST compared to REC. Peak HR at the end of the 5 km time-trial was lower than baseline by week 2 and remained suppressed over the following 2-weeks of overload training; however, only peak HR at week 4 was different from recovery at week 5. Using the Hooper-Mackinnon well-being scale, subscales of fatigue (P<0.001, W=0.65), muscle soreness (P<0.001, W=0.79), training enjoyment (P=0.01, W=0.44), irritability (P=0.001, W=0.40), and overall health (P=0.003, W=0.37) were altered across the 5-weeks of training, while stress (P=0.1, W=0.17) and sleep (P=0.7, W=0.05) were not. As can be seen in Table 1, most of the detrimental well-being scores were the highest at POST and recovered to baseline by REC.

With only ~5-7 days of recovery after overload training at REC, participants improved their 5 km time-trial average power from POST by 19±9W (P=0.001, $\eta_p^2=0.82$), and from PRE by 12±9W (P=0.01, $\eta_p^2=0.66$) (Table 1). Peak lactate at the end of the 5 km time-trial also recovered, with no significant differences between PRE and REC.

Exercising CGM Glucose and Substrate Utilization with Overreaching

Minute-by-minute glucose and glucose AUC during the LSCT and the 5 km time-trial are presented in Figure 3. Due to sensor or software malfunctions, reliable CGM glucose data was only available for n=8 participants prior to and during the LSCT, and n=9 in the 5 km time-trial. Fifteen min following 50g glucose ingestion, but prior to the LSCT start, CGM glucose was not
different across visits (see Table 1). Exercising CGM glucose was reduced in the LSCT at POST across the submaximal test ($P=0.047, \eta^2_p =0.36$; Figure 3A). There was a trend toward a reduction in glucose at POST compared to REC in the 5 km time-trial ($P=0.07, \eta^2_p =0.28$; Figure 3C), but with considerable individual variability in response. End-of-stage (single time-point) lactate and glucose in the LSCT, and glucose in the 5 km time-trial were not significantly different across PRE, POST, or REC weeks (see Table 1), and changes in end-of-stage glucose were unrelated to changes in cycling power output or lactate from PRE to POST. Plasma epinephrine at the end of the 5 km time-trial was non-significantly reduced from PRE to POST ($P=0.09, \eta^2_p =0.29$); however, only n=8 samples were available for analysis (see Figure 4).

Figure 3. CGM glucose concentration at each minute of the Lamberts and Lambert Submaximal Cycling Test (LSCT) (A) and 5 km time-trial (C), and glucose area-under-the-curve for the LSCT (B) and 5 km time-trial (D) before (PRE) and after (POST) 3 weeks of overload training and following 1 week of recovery training (REC). Samples available for analysis, n=8 for the LSCT and n=9 for the 5 km time-trial.
Figure 4. Plasma epinephrine at the end of a 5 km time-trial before (PRE) and after (POST) three weeks of overload training and following one week of recovery training (REC). Samples available for analysis, n=8.

Metabolic variables assessed via indirect calorimetry during the LSCT and 5 km time-trial are presented in Figure 5. In the LSCT, VO₂ was unchanged at 60% of HRmax (P=0.5, η² =0.07), 90% of HRmax (P=0.2, η² =0.16), and during the time-trial (P=0.06, η² =0.25) across PRE, POST and REC weeks; however, there was a clear elevation at 80% of HRmax at POST compared to PRE (P=0.03, η² =0.51; Figure 5, column A). VCO₂ was unchanged across PRE, POST, and REC at 60% of HRmax (P=0.4, η² =0.1) and 90% of HRmax (P=0.3, η² =0.13) in the LSCT. VCO₂ was altered at 80% of HRmax in the LSCT (interaction, P=0.02, η² =0.32), but post hoc tests were not significantly different between weeks. In the 5 km time-trial, VCO₂ was reduced at POST compared to PRE (P<0.001, η² =0.80) and REC (P=0.001, η² =0.74). RER was lower at POST compared to REC at 60% of HRmax (P<0.001, η² =0.74), 80% of HRmax (P=0.003, η² =0.68), and trending at 90% of HRmax (P=0.07, η² =0.34) in the LSCT. RER was reduced at POST compared to PRE (P<0.001, η² =0.86) and REC (P=0.001, η² =0.73) in the 5 km time-trial. VE was unchanged at 60% of HRmax (P=0.2, η² =0.15) and 90% of HRmax (interaction P=0.05, η² =0.26, no significance with post hoc tests), but was elevated at POST compared to PRE (P=0.02, η² =0.56) and REC compared to PRE (P=0.02, η² =0.53) at 80% of HRmax. Finally, VE was elevated at REC compared to POST in the 5 km time-trial (P=0.007, η² =0.62).
Figure 5. Alterations in mean oxygen consumption ($\dot{V}O_2$; column A), carbon dioxide production ($\dot{V}CO_2$; column B), respiratory exchange ratio (RER; column C), and ventilation (VE; column D) during the Lamberts and Lambert submaximal cycling test (LSCT) and 5 km time-trial cycling before (PRE) and after (POST) 3 weeks of overload training, and following 1 week of recovery training (REC).
Resting Measures and Markers of Low Energy Availability

There were no changes in resting and fasted HR, HRV, resting epinephrine, CGM glucose, or markers of low energy availability from PRE to POST overload training, or following REC (Table 2). There was little concern that results were driven by overt low energy availability as only two individuals included in the study had a reduction in all three markers of low energy availability (RMR, body mass, and leptin), and one participant had a reduction in 2 markers (leptin and body mass). Changes in body mass, RMR, and leptin were unrelated to changes in LSCT and 5 km time-trial power output, or CGM glucose during cycling between PRE- and POST-overload training. The 3 participants with ≥ 2 markers of low energy availability had a mean reduction in 5 km time-trial power output of Δ-2±2W (compared to Δ-7±10W of full group), HR peak of Δ-5±4 bpm (compared to Δ-6±3bpm of full group), peak lactate of Δ-5.1±1.1 mmol/L (compared to Δ-3.0±2.0mmol/L of full group), and well-being score of Δ11±1.7a.u (compared to Δ10±5a.u. of full group) following overload training. Removal of these participants did not alter the CGM glucose or cardiorespiratory-metabolic findings during exercise. Reductions in RMR were strongly associated with reductions in body mass (r=0.7, P=0.02), but not ΔlnRMSSD (r=-0.01, P=0.98).

Table 2. Resting autonomic and metabolic markers before (PRE) and after (POST) 3 weeks of overload training and after 1 week of recovery training (REC)

<table>
<thead>
<tr>
<th></th>
<th>PRE</th>
<th>POST</th>
<th>REC</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR (bpm)</td>
<td>55±6</td>
<td>53±7</td>
<td>54±7</td>
</tr>
<tr>
<td>lnRMSSD (ms)</td>
<td>4.2±0.6</td>
<td>4.1±0.7</td>
<td>3.9±1.0</td>
</tr>
<tr>
<td>Resting Metabolic Rate (kcal/d)</td>
<td>1834±205</td>
<td>1889±264</td>
<td>1860±242</td>
</tr>
<tr>
<td>Predicted RMR (%)</td>
<td>104±10</td>
<td>108±10</td>
<td>106±8</td>
</tr>
<tr>
<td>Resting V̇O₂ (mL/min)</td>
<td>263±28</td>
<td>274±39</td>
<td>268±33</td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>73.5±10.0</td>
<td>73.0±10.0</td>
<td>73.4±9.7</td>
</tr>
<tr>
<td>Leptin (ng/mL)</td>
<td>1.9±0.8</td>
<td>1.5±0.7</td>
<td>2.1±0.9</td>
</tr>
<tr>
<td>Epinephrine (ng/mL)</td>
<td>0.05±0.03</td>
<td>0.06±0.02</td>
<td>0.06±0.02</td>
</tr>
<tr>
<td>Fasted CGM glucose (mmol/L)</td>
<td>4.5±0.8</td>
<td>4.4±0.3</td>
<td>4.6±0.7</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>46.1±2.3</td>
<td>44.8±2.9</td>
<td>44.7±3.6</td>
</tr>
</tbody>
</table>
Discussion

This investigation sought to determine whether carbohydrate utilization is altered during exercise in overreached endurance athletes, and whether CGM sensors may complement other monitoring techniques for detecting overreaching status. In accordance with our hypothesis, metabolic disturbance was evident during exercise after a period of functional overreaching. Specifically, RER was reduced with functional overreaching relative to REC during the 60 and 80% HRmax stages during the LSCT. Further, glucose levels assessed using CGM were reduced during submaximal exercise during the LSCT and not at rest, indicating a possible use of such sensors to indicate functional overreaching status during submaximal exercise. Finally, when assessing different monitoring techniques to detect overreaching, the suppression of peak exercising lactate, peak exercising HR, and total well-being remain the most sensitive markers, with the LSCT being insufficiently sensitive to detect overreaching in the present study. The combination of exercising HR, well-being or mood, and submaximal exercising CGM may provide an easy and non-invasive way to monitor for overreaching-status in endurance athletes.

Alterations in substrate utilization with overreaching

Overreaching is characterized by a reduction in sport performance, with concomitant reductions in submaximal and maximal exercising lactate and HR (13). While an acute reduction in circulating lactate during exercise is a known marker of overreaching (3, 5, 6, 13), further investigation into altered exercise metabolism and substrate utilization during functional or non-functional overreaching has received little attention to date. In a longitudinal study on elite rowers, it was demonstrated that athletes who were underperforming had alterations in carbohydrate metabolism during exercise that progressed to altered lipid and protein metabolism with further training; however, markers of low energy availability were not studied concomitantly (32). Following a 3-week high-intensity overload training period in recreationally-active individuals, it was demonstrated that intrinsic respiration from isolated skeletal-muscle mitochondria was reduced at rest, and that exercising capillary glucose concentration was suppressed during high-intensity cycling. The participants had elevations in resting muscle glycogen stores, indicating that glycogen availability was unlikely to be the primary mechanism of impairment (14, 15). Our present findings may support this work, as the functionally overreached athletes also demonstrated reductions in exercising interstitial glucose during submaximal exercise despite the ingestion of 50 g of glucose 15 min prior to
cycling in all visits, with reductions in RER from POST to REC in the 60 and 80% stages of the LSCT, and marked reductions in V\(\dot{CO}_2\) during the 5 km time-trial. Importantly, these were independent of alterations in primary markers of energy availability, and were not detected at single time points at rest. The reduction in V\(\dot{CO}_2\) during the 5 km time-trial at POST is not explained by altered ventilatory patterns, as VE was unchanged from PRE-to-POST despite the robust reduction in V\(\dot{CO}_2\). While this change during exercise could represent a normal response to training and improvement in fitness, after only 5-7 days of recovery, submaximal exercise glucose levels rebounded, and RER was elevated in both submaximal and maximal exercise conditions. It is possible that impaired mitochondrial bioenergetics may drive altered substrate utilization following high-intensity overload training (14, 15); however, the plausibility of this effect has been contested (33) and further research on overreached athletes is required to confirm this mechanism. The reduction in circulating carbohydrate during submaximal exercise assessed through CGM and carbohydrate oxidation assessed via indirect calorimetry with overreaching could also be explained by a reduction in circulating epinephrine, which has previously been demonstrated in overreached male triathletes (5, 6). In addition to intramuscular factors such as free ADP, systemic factors including elevations in circulating epinephrine during exercise upregulate glycogenolysis, increasing glycogenolytic/glycolytic flux and the subsequent production of lactate and pyruvate (34). As such, a suppression in circulating epinephrine may contribute to the observed reduction in whole body carbohydrate oxidation during exercise, as well as the reduction in circulating lactate, and exercising heart rate with overreaching (17). While we did not observe a statistically significant reduction in epinephrine during exercise in the present investigation (P=0.09, \(\eta_p^2=0.29\)), the statistical significance was likely limited by the small sample size and individual variability in response. Future research should investigate this reduced adrenergic response to exercise in overreached athletes.

**Energy Availability**

The recognition that overreaching and low-energy availability often co-occur (11, 12), but have separate aetiologies, is an important distinction that should be made in the field. From a metabolic perspective, it is known that insufficient energy intake relative to exercising energy expenditure will result in rapid reductions in leptin, free and total T3, and IGF-1, which in turn suppresses RMR, fasting glucose and insulin, and elevates circulating glycerol and free fatty acids (35). During low energy availability, RMR is depressed (35); however, it is currently unknown whether overreaching can independently reduce RMR through altered autonomic
function (12). Reductions in body mass and leptin should occur exclusively with an energy or carbohydrate deficit, and not exercise stress alone (16, 36). Though this investigation would have benefitted from the assessment of energy intake and expenditure, there were no group mean changes to any of the markers of low energy availability, and the effects on the few subjects who showed markers of low energy availability were small. While further research is certainly required to disentangle the mechanisms of low energy availability and training stress and their independent effects on performance, the present investigation and those of Flockhart et al. (14, 15) suggest altered exercising metabolism from overreaching is likely not fully explained by insufficient energy availability.

Monitoring techniques

Research into monitoring tools for overreaching-status in endurance athletes has been obscured by the search for a resting marker of overreaching through hematological or autonomic measures (17, 37), and a misunderstanding of overreaching and its relationship with low energy availability (11, 12) and/or overtraining syndrome (10). However, it is now clear that functional and non-functional overreaching represent a state of fatigue that may be indistinguishable from normal acute training fatigue at rest, but becomes apparent during submaximal or maximal exercise (17, 19). As opposed to repeated maximal testing, which is impractical for use with high-level athletes, the LSCT has promise as a monitoring tool as it can be employed as a standardized warm-up (38); however, while there were small elevations in RPE and average power output across the overload training period in the present investigation, these were not statistically significant. Standardizing the exercise load (e.g., power output) and observing the resultant HR response may be an easier method to detect overreaching than the LSCT, as it is difficult to adjust exercise load in response to fluctuations in HR with precision. Mood states have consistently been shown to be altered with overreaching, yet a mood state or readiness scale may not distinguish acute fatigue from overreaching on its own (2, 19). An acute suppression of lactate and HR at submaximal and maximal exercise intensities has been demonstrated to best discriminate between overreached and normally-trained individuals when compared to many training-status markers (13), and remains the best marker of overreaching to date. Finally, with the advent of CGM for use with non-diabetic athletes, interstitial glucose could provide a further monitoring tool for coaches and athletes to use in combination with a standardised breakfast and warm-up exercise, and in combination with HR and a subjective assessment of fatigue, particularly if lactate testing is unavailable. It is important to note that we did not see significant alterations in single-point resting or end-
exercise interstitial glucose following overload training, and as such continuous data during exercise-stress remains important for assessing disturbed physiology with overreaching.

**Limitations**

A limitation of the current investigation is the small sample size, which likely precluded our ability to see an effect in some measures. However, this sample size is typical of the field, and represents the difficulty of performing this type of research. The recovery period at week 5 was only ~5 days in some participants due to difficulties in data-collection scheduling, which was likely insufficient for full recovery, but may approximate a pre-competition taper for some athletes. Training intensity was not specifically assessed over the course of the 5-week study; however, participants were instructed to maintain the intensity of their training sessions outside the laboratory for the 3 overload weeks, and additive training intensity occurred in the supramaximal sprint-interval sessions, which were supervised in the lab. We were unable to conduct the same study on a normally-training control group; therefore, it is unknown if regular training or acute-fatigue would have the same effect as overreaching on the novel metabolic outcome measures presented herein. The requirement of multiple CGM devices per participant across the training block could have introduced variability into the glucose measures; however, separate Freestyle Libre sensors (the platform on which the Supersapiens device is made) have been demonstrated to provide similar results in an individual when worn simultaneously (39). In the current study, we did not assess CGM interstitial glucose in the leg, but related work suggests a potentially differential effect of glucose monitoring in proximity to the working muscle groups (40). Diet could not be controlled in this study; however, participants were instructed to consume greater calories, and in particular carbohydrate, during the overload training weeks. Further, all testing was performed following an overnight fast, and a standardized glucose beverage was consumed at a consistent time interval prior to exercise. Finally, while female participants were recruited for the study, we were unable to perform sex-difference analyses due to the small sample-size.

**Conclusion**

Overreaching in endurance sport has negative consequences on sport performance, health, and training adaptation (3, 8, 17). This investigation demonstrated that carbohydrate utilisation is likely altered during exercise with overreaching in endurance-trained athletes, with a shift towards fat oxidation, and a reduction in interstitial fluid glucose concentrations during HR-matched submaximal exercise. This is in accordance with similar findings by Flockhart et al.
(14, 15) following 3 weeks of high-intensity interval training that resulted in performance stagnation. The use of CGM during submaximal exercise may provide an additional non-invasive monitoring tool for the prevention of overreaching in endurance athletes.

Authors Contributions:
Contributed to conception and design: AMC, JFB
Contributed to acquisition of data: AMC, KMAT, MMG, REB, CP, AAR, CPC
Contributed to analysis and interpretation of data: AMC, KMAT, SMF, CP
Drafted and/or revised the article: All authors
Approved the submitted version for publication: All authors

The authors have no conflicts of interest to declare. Supersapiens and TT1 Products had no influence, financial or otherwise, on the collection, results, or interpretation of the findings.

**Funding information**
This research was supported by a grant from the Natural Science and Engineering Research Council of Canada. The continuous glucose monitoring sensors used in this study were provided by Supersapiens and TT1 Products Inc.

**Data and Supplementary Material Accessibility**
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES


